en · de · es · pt
tb-500-notes.peptides6088.com › Topic › Tb-500 Identity And Naming Background — What the Evidence Shows

Tb-500 Identity And Naming Background — What the Evidence Shows

By Editorial Desk · published 2026-01-20 · last reviewed 2026-02-23 · Topic

reversed-phase HPLC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2026-02-23. Where a claim depends on a specific study, the study is described rather than over-claimed.

TB-500 Identity and Naming Background

Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.

Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.

TB-500 Identity and Chemical Background

TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.

Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.

Tb-500 at a glance

PropertyValueNotes
Name typeCommercial trade nameNot a systematic chemical identifier
Parent peptideThymosin beta-443-residue natural peptide
Common fragment sequenceLKKTETQMaps to part of the actin-binding region
Molecular size classRoughly 0.8-1.0 kDaDepends on exact fragment and terminal modification
Regulatory statusProhibited in sportGrouped with peptide hormones in many frameworks

Handling, Stability and Analytical Detection

Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.

Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.

Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.

Related pages on this site

Handling, Storage and Analytical Checks

Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.

Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.

TB-500 Identity and Molecular Background

Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.

TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.

Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.

Background from the literature

== Diagnosis == Schwartz–Jampel syndrome is diagnosed on the basis of characteristic facial features, skeletal features and myotonia. Blood tests may show elevated serum creatine kinase or aldolase. X-rays, muscle biopsy or electromyography (EMG) may be useful. Genetic testing for the HSPG2 gene may confirm diagnosis.

He added that Afghanistan had taken serious measures to ensure its territory was not used against Pakistan and said its military actions were defensive. Pakistan's Defence Minister, Khawaja Asif, implicitly confirmed that indirect talks with the Afghan Taliban were taking place through third-party mediators, although he described the process as unstructured and informal. He added that if the efforts failed to secure peace, Pakistan could return to its previous approach and escalate military operations in parts of Afghanistan. Pakistani military claimed to have killed 10 TTP militants in an operation in Khyber District and three more in Bannu. On 31 March, Taliban and Pakistani forces clashed in Dangam District of Kunar Province. On 1 April, 4 police personnel and 5 civilians were injured in an improvised explosive device (IED) blast carried out by Pakistani Taliban in Pakistan's Lakki Marwat district. On 2 April, Pakistani officials said that they foiled an infiltration attempt along the Afghanistan–Pakistan border, killing eight militants and seizing a large quantity of weapons and ammunition. That same day, Taliban and Pakistani officials confirmed that they were holding preliminary talks mediated by China in Ürümqi. Pakistani officials described the talks as working-level and said that they had sent their mid-level delegation to take part in the talks.

the sclerotome, which forms cartilage, the syndetome, which forms tendons, the myotome, which forms skeletal muscle, the dermatome, which forms the dermis as well as skeletal muscle, and endothelial cells.

Sources: en.wikipedia.org

Reference notes

Caldwell Dyson was assigned for her second space flight on November 21, 2008. Her second space mission consisted of a six-month trip to the International Space Station. Caldwell Dyson successfully lifted off on April 2, 2010, from the Baikonur spaceport on board the Soyuz TMA-18 as Flight Engineer 2 with Soyuz Commander Aleksandr Skvortsov and Flight Engineer 1 Mikhail Korniyenko. Following a two-day rendezvous and docking maneuver with the ISS, she joined Expedition 23 as a flight engineer and transferred on June 2, 2010, to Expedition 24 again as a flight engineer after the departure of the Soyuz TMA-17. During the first half of her flight, Caldwell Dyson and the Expedition 23 crew were joined by the STS-131 crew from April 7 to April 17. This period was the first and only time that four women were together on board the same spacecraft: Caldwell Dyson, NASA astronauts Stephanie Wilson and Dorothy Metcalf-Lindenburger, and JAXA astronaut Naoko Yamazaki. From May 16 to May 23, the second and last Space Shuttle visiting mission for Caldwell-Dyson's flight, STS-132, joined the Expedition 23 crew for the installation of the Russian-built module Rassvet. The second half of Caldwell Dyson's mission was marked by the failure of a coolant pump at the beginning of August. Caldwell Dyson performed her first spacewalk on August 7, 2010, with NASA astronaut Douglas Wheelock. The task for this first of three contingency EVAs was to prepare the malfunctioning coolant pump for replacement on the next spacewalks; this took place on August 11, 2010, and August 16, 2010.

Alistair Barkley who goes on the run with Eddie when they are framed for Alistair's murder and the destruction of his laboratory Fred Ward as FBI Agent Leon Ford, who leads the investigation to discover the cause of the destruction of the laboratory; initially focusing on Eddie and Lily, he soon suspects the involvement of government organizations Kevin Dunn as FBI Agent Doyle, Ford's assistant in the investigation who helps Ford track down Eddie, Lily, and later, C-Systems Brian Cox as Lyman Earl Collier, Chairman of C-Systems Research who is behind the conspiracy to keep the hydrogen power plant a secret Joanna Cassidy as Maggie McDermott, an old friend of Eddie's who lives in an observatory in Wisconsin, where Eddie and Lily escape to after a warrant is issued for their arrest Chelcie Ross as FBI Agent Ed Rafferty Nicholas Rudall as Dr. Alistair Barkley, head of the project to develop energy from the water who is later suffocated Tzi Ma as Lu Chen, Project Manager on the Hydrogen Project and Dr. Barkley's right-hand man; when Barkley is killed, Dr. Chen is kidnapped and forced to work at C-Systems Krzysztof Pieczyński as Lucasz Screbneski, the scientist on the original project who is secretly working for C-Systems Eddie Bo Smith Jr. and Danny Goldring as Yusef Reed and Clancy Butler, Collier's right hand men for C-Systems Margaret Travolta as Anita Fermi, Shannon's personal assistant. In addition, Michael Shannon and Neil Flynn make appearances as a van driver and a Wisconsin State Police Trooper, respectively.

Stilton blue cheese was first sold in the village of Stilton in England, but there is little evidence it was ever made there. Stilton cheese is made from pasteurized milk; a similar, less commonly found, blue cheese made from raw milk and without factory-produced rennet is Stichelton. In addition to being inoculated with Penicillium roqueforti to give it the blue vein characteristic, research has shown that other microbiota which are relatives of Lactococcus lactis, Enterococcus faecalis, Lactobacillus plantarum, Latilactobacillus curvatus, Leuconostoc mesenteroides, Staphylococcus equorum, and Staphylococcus sp. can also be found in blue Stilton cheese. Some important microbiota contribute to the aromatic profile such as those of the Lactobacillus genus due to their production of volatile compounds. During ripening, free fatty acids increase in amount, which contributes to the characteristic flavor of blue cheeses due to fat breakdown by Penicillium roqueforti. There is also uninoculated white Stilton cheese.

Sources: en.wikipedia.org

Reference notes

=== Preregistration === Orenetide (BP-101; BP101; Libicore; Desirix) – undefined mechanism of action (synthetic small peptide) – female sexual dysfunction [1] [2] Tadalafil oral film (AQST-119; Exordia) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [3] Tadalafil oral film (Exordia; INT-007; INT0007; INT0007/2006) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [4]

To produce the drug, genes coding for the chimeric mAbs were inserted into viral vectors, and tobacco plants are infected with the viral vector encoding for the antibodies, using Agrobacterium cultures. Subsequently, antibodies are extracted and purified from the plants. Once the genes encoding the chimeric mAbs are in hand, the entire tobacco production cycle is believed to take a few months. The development of these production methods was funded by the U.S. Defense Advanced Research Projects Agency as part of its bio-defense efforts following the 9/11 terrorist attacks.

Resting metabolic rate generally composes human 60 to 75 percent of TDEE. Because adipose tissue does not use much energy to maintain, fat free mass is a better predictor of metabolic rate. A taller person will typically have less fat mass than a shorter person at the same weight and therefore burn more energy. Men also carry more skeletal muscle tissue on average than women, and other sex differences in organ size account for sex differences in metabolic rate. Obese individuals burn more energy than lean individuals due to increase in the amount of calories needed to maintain adipose tissue and other organs that grow in size in response to obesity. At rest, the largest fractions of energy are burned by the skeletal muscles, brain, and liver; around 20 percent each. Increasing skeletal muscle tissue can increase metabolic rate.

=== Complications === A number of complications may occur from cholecystitis if not detected early or properly treated. Signs of complications include high fever, shock and jaundice. Complications include the following:

Sources: en.wikipedia.org

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.

What does research on the fragment actually measure?

Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.

Why does the name cause confusion?

Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.

Is TB-500 the same as thymosin beta-4?

No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.

Network